Health & Fitness
Health and Fitness
Health and Fitness
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Patient Home Monitoring (PHM) Releases an Updated Presentation in Advance of Meetings to Introduce Robert Kusher, Its CEO to th
March 26, 2013 20:54 ET
Patient Home Monitoring (PHM) Releases an Updated Presentation in Advance of Meetings to Introduce Robert Kusher, Its CEO to the Canadian Capital Markets
SAN FRANCISCO, CALIFORNIA--(Marketwire - March 26, 2013) - Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home management solutions for patients with chronic disease, today released an updated presentation in advance of meetings to introduce Mr. Robert Kusher, PHM's newly appointed CEO, to the capital markets in Vancouver, Toronto, and Montreal. To set up a meeting, please contact Mr. Michael Dalsin, Chairman of PHM using the contact information below. The presentation can be accessed by visiting the following link:
[ http://www.phmhometesting.com/investor/public/dl/PHM%20Meter%20Prez.pdf ]
About PHM
PHM is a healthcare services company focused on providing in-home services for patients suffering from chronic disease. PHM's main revenue line is offered to patients on blood thinner medications such as Coumadin® or warfarin. PHM has recently announced it will embark on a process to expand services to its patient base in both the US and Canada.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
